Decheng Capital LLC Has $7.08 Million Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Decheng Capital LLC reduced its stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 24.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,338,095 shares of the company's stock after selling 770,000 shares during the quarter. Zentalis Pharmaceuticals accounts for 1.5% of Decheng Capital LLC's investment portfolio, making the stock its 14th biggest holding. Decheng Capital LLC owned about 3.28% of Zentalis Pharmaceuticals worth $7,084,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Barclays PLC increased its position in Zentalis Pharmaceuticals by 18.5% during the 3rd quarter. Barclays PLC now owns 75,395 shares of the company's stock worth $277,000 after purchasing an additional 11,748 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Zentalis Pharmaceuticals by 22.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company's stock worth $1,507,000 after buying an additional 91,152 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter worth about $76,000. SG Americas Securities LLC grew its holdings in shares of Zentalis Pharmaceuticals by 115.6% during the fourth quarter. SG Americas Securities LLC now owns 56,389 shares of the company's stock worth $171,000 after buying an additional 30,240 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $68,000.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL traded up $0.05 during mid-day trading on Thursday, reaching $1.47. 404,660 shares of the company's stock traded hands, compared to its average volume of 1,542,356. The business's 50-day moving average price is $1.60 and its 200-day moving average price is $2.47. The stock has a market capitalization of $105.20 million, a P/E ratio of -0.59 and a beta of 1.80. Zentalis Pharmaceuticals, Inc. has a 12 month low of $1.01 and a 12 month high of $13.24.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its earnings results on Wednesday, March 26th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.09. The firm had revenue of $26.90 million for the quarter. Equities research analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insiders Place Their Bets

In other news, Director Scott Dunseth Myers acquired 21,000 shares of the stock in a transaction on Wednesday, April 30th. The shares were purchased at an average cost of $1.40 per share, for a total transaction of $29,400.00. Following the transaction, the director now owns 281,192 shares in the company, valued at approximately $393,668.80. This trade represents a 8.07 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jan Skvarka acquired 60,000 shares of the stock in a transaction on Friday, January 31st. The shares were purchased at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the transaction, the director now owns 149,551 shares in the company, valued at approximately $257,227.72. This represents a 67.00 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 101,000 shares of company stock worth $178,200. 3.60% of the stock is owned by insiders.

Analyst Ratings Changes

ZNTL has been the topic of a number of recent research reports. Wedbush reaffirmed a "neutral" rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, March 28th. Wells Fargo & Company reduced their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 30th. HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 27th. Finally, UBS Group reduced their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $8.24.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.